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ScienceDirectKaposi’s sarcoma (KS) is an endothelial tumor causally
linked to Kaposi’s sarcoma herpesvirus (KSHV) infection. At
early stages of KS, inflammation and aberrant
neoangiogenesis are predominant, while at late stages the
disease is characterized by the proliferation of KSHV-
infected spindle cells (SC). Since KSHV infection modifies
the endothelial cell (EC) identity, the origin of SCs remains
elusive. Yet, pieces of evidence indicate the lymphatic origin.
KSHV-infected ECs display increased proliferative,
angiogenic and migratory capacities which account for KS
oncogenesis. Here we propose a model in which KSHV
reprograms the EC identity, induces DNA damage and
establishes a dysregulated gene expression program
involving interplay of latent and lytic genes allowing
continuous reinfection of ECs attracted to the tumor by the
secretion of virus-induced cellular factors.
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Kaposi’s sarcoma and identification of its
associated herpesvirus
Kaposi’s sarcoma (KS) was named after a Hungarian
dermatologist, Moritz Kaposi, who first described five
cases of this multifocal, pigmented tumor of the skin.
KS remained a rare disease until the 1980s when an
aggressive form was observed among the AIDS
patients. The high number of cases together with the
bad prognosis associated with AIDS-KS promptedCurrent Opinion in Virology 2017, 26:156–162 researchers on studying the disease in detail. Particular
efforts were put into the identification of KS causal
agent and in 1994 Chang and Moore identified it as a
newly discovered virus named Kaposi’s sarcoma her-
pesvirus (KSHV) [1]. Classified as a gamma2 herpesvi-
rus [2], KSHV has been subsequently associated also
with two lymphoproliferative disorders: primary effu-
sion lymphoma (PEL) and multicentric castleman dis-
ease (MCD) [3,4].
KSHV displays a biphasic life cycle with a latent and a
lytic phase. Although latency represents the default mode
of persistence in the tumor cells, both phases contribute
to KS pathogenesis. Since many reviews [5–8] recently
discussed the molecular mechanisms of KS induced
tumorigenesis, here we will focus on the reprogramming
and manipulation of endothelial cells and its contribution
to KS pathogenesis.
KS: an angiogenic, inflammatory tumor of the
endothelium
Different forms of KS can be distinguished according to
their epidemiological  characteristics. In the sub-Saharan
Africa KS is a common tumor among men and children
(epidemic KS), whereas in the Mediterranean basin a
milder form of KS affects primarily elderly men
(endemic KS) [9]. The clinical features of KS become
more aggressive when it occurs in immunosuppressed
patients, such as transplant recipients (iatrogenic KS)
and AIDS patients (AIDS KS) [10,11]. In these individ-
uals, the lesions are life threatening because of the
visceral involvement [11].
Microscopically, the different forms of KS are indistin-
guishable and display rather stage-specific  features. At
the early phase, KS manifests as patches characterized
by abundant and aberrant angiogenesis. The abnormal
blood vessels are leaky, thus accounting for the extrava-
sation of erythrocytes and inflammatory cells that popu-
late the lesion (Figure 1). The early KS patch appears as
a flat, red macula (located in the limbs or face) and no
evident tumor mass is present. In these patches, as little
as 10% of the tumor is composed of KSHV-infected
cells. When progressing toward advanced stages, KS
develops into plaques and then into nodules. Here,
90% of the cells are KSHV-positive. The tumor mass
is macroscopically evident and composed of so-called
spindle cells (SCs) [12] that is, KSHV-infected cellswww.sciencedirect.com
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Schematic model of a KS lesion (a) KSHV virions infect endothelial cells. (b) Early KS lesion: KSHV infected endothelial cells display the typical
spindle morphology and produce pro-angiogenic and inflammatory cytokines that chemotactically attract immune cells to the tumor site. Aberrant
angiogenesis takes also place and causes the extravasation and accumulation of red blood cells. (c) Late KS lesion: the tumor is composed of
KSHV-infected SCs. Majority of the SC are in a latent/dysregulated lytic phase, produce inflammatory and angiogenic chemokines and express
many oncogenic viral proteins. Only a small subset of SCs are in a lytic phase and they produce new infectious virions for the maintenance of the
population of infected cells.with characteristic, elongated (spindle) morphology
(Figure 1).
On the cellular origin of KS spindle cells
Different studies reported that SCs express a number of
endothelial cell (EC) markers, for example, CD31, CD34
and factor VIII but they also harbor, to a lesser extent,
lineage specific signatures of smooth muscle cells
(a-SMA), monocytes/macrophages, dendritic cells as well
as fibroblasts and mesenchymal cells [13,14,15–18].
The gene expression signature of KS SCs indicates an
endothelial origin; however, it is still a matter of debate
whether the original precursor belongs to the blood or
lymphatic lineage. KSHV infection of lymphatic ECs
(LECs) triggers the reprogramming toward a less differ-
entiated, immature blood ECs (BECs) phenotype, making
KSHV-LECs more similar to BECs than their uninfected
counterpart. KSHV-infected BECs, vice versa, express
lower levels of blood vascular markers such as CXCR4
and Neuropilin-1 and show an increase in lymphatic
markers like Prox1, VEGFR3, podoplanin and LYVE1
(reviewed in [19]). KSHV infection of ECs manipulates
the EC differentiation program driving each cell type
away from its original, mature phenotype and pushing it
toward an undifferentiated, even mesenchymal-like cell
type with mixed identity (reviewed in [20]). As a result,www.sciencedirect.com KSHV-infected ECs display tumorigenic properties such
as increased angiogenic, invasive and migratory abilities
and, although not fully immortalized [21,22], they exhibit
a growth advantage over their uninfected counterparts
[14,23].
Several observations suggest that LECs rather than BECs
are the main precursor of SCs. First, the localization of KS
lesions in tissues rich in lymphatics (e.g. skin and mucosa)
[24–26]. Second, KSHV-LECs exhibit, in culture, the
elongated (spindling) morphology, resembling KS-SCs,
whereas in BECs the morphology is not significantly
altered by KSHV infection. Third, LECs can be more
efficiently infected and harbor a higher viral copy number
[13]. In Addition, the comparison of the gene expression
profile of nodular KS lesion with those of BECs and LECs
showed that KS signature resembles, at least at this stage,
more LECs than BECs [13]. Moreover, three-dimen-
sional culture of KSHV-LEC as spheroids has been
shown to recapitulate many of the features found in
the KS lesions, among others the differential expression
of endothelial and mesenchymal markers in virus-
infected cells and the increased tumorigenic invasiveness
in the 3D matrix [14].
Still, the presence of KSHV-infected BECs in KS lesions
cannot be ruled out. KSHV-BECs are found in the earlyCurrent Opinion in Virology 2017, 26:156–162
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of aberrant blood vessels. However, in the advanced
lesions, although representing the majority of the tumor
mass, KSHV-positive SCs were not found in the blood
vessels [27]. One could hypothesize that KSHV infects
both BEC and LEC at the early stages of the disease, but
then KSHV-LECs, more susceptible hosts for the virus,
propagate more efficiently and become the predominant
cell type in advanced lesions. In agreement with this
hypothesis is a study in which Prox1 expression, a marker
of lymphatic differentiation (see below), was investigated
in AIDS-oral KS. Here, Prox1, almost absent in the early
KS patches, increased significantly in the advanced pla-
que and nodular stages [28].
Another possibility is that KS-SCs arise from the infection
of circulating EC precursors (ECPs), CD34-positive bone
marrow-derived cells that home into angiogenic sites
where they differentiate into mature ECs [19]. In support
of this hypothesis: first, ECPs isolated from KS patients
were found positive for KSHV, retained the virus after
several passages and were able to sustain lytic replication
[29]; second, ECPs from KS patients displayed higher
angiogenic potential in vitro [30]; third, KSHV-positive,
CD34+, adherent SCs were found in the blood mononu-
clear cell fraction [31]; fourth, the multifocal nature of KS
lesions occurring independently in different body areas
and preferentially in the surgical scares [25,32] or other
sites of previous inflammation and angiogenesis, where
the ECPs are recruited.
Molecular mechanisms of KSHV-induced
trans-differentiation of endothelial cells
The trans-differentiation induced by KSHV represents an
abnormal pathological process that can endow ECs with
tumorigenic properties (increased proliferation, invasive-
ness and angiogenic potential), thus contributing to KS
oncogenesis. In order to manipulate the EC-lineage iden-
tity, KSHV infection interferes with the expression of
factors responsible for the differentiation and mainte-
nance of specific EC types.
The transcription factor prospero homeobox 1 (Prox1) has
been identified as the master regulator of the LEC fate
[33]. Prox1 is required for the development of the lym-
phatic vasculature [34,35], and it also maintains the LEC
cellular identity [36,37]. Ectopic expression of Prox1 in
BECs drives the expression of LEC-specific markers
(podoplanin, VEGFR3, LYVE1) and suppresses those
accountable for the BEC signature [33,38].
KSHV modulates Prox1 expression both in LECs and
BECs with opposing results [13,14,19,39,40]. In BECs
Prox1 is not expressed under normal conditions, however,
upon KSHV infection, Prox1 expression is induced and
activates at least part of the LEC-differentiation program.
In LECs, normally expressing high levels of Prox1, KSHVCurrent Opinion in Virology 2017, 26:156–162 infection results in the downregulation of this transcrip-
tion factor. The molecular mechanisms that govern Prox1
levels during KSHV infection have been recently eluci-
dated. In KSHV-BECs Prox1 expression is driven by the
virus-induced upregulation of IL3Ra, which controls
Prox1 through Stat5. In KSHV-LECs, however, IL3Ra
does not affect the already high Prox1 expression that is
regulated by the Notch1-Hey1 circuit. The KSHV-driven
activation of Notch1, triggered by the viral proteins
vFLIP and vGPCR [14,41], is responsible for the down-
regulation of Prox1 in infected LECs but does not affect
Prox1 levels in KSHV-BECs. Thus, the simultaneous
activation of Notch1 and ILR3a signaling by KSHV,
which contributes to the differential regulation of Prox1
levels, leads to lymphatic reprogramming of BECs and
induces blood vascular differentiation in LECs.
Another transcription factor with a pivotal role in KSHV-
induced trans-differentiation of ECs is the musculo-apo-
neurotic-fibrosarcoma oncogene homolog (MAF).
Expressed in LECs but not in BECs, MAF represses
the BEC-specific genes, thus contributing to the mainte-
nance of the LEC identity [38,39]. In a study aiming to
identify new KSHV miRNA targets in LECs, MAF was
among the top three downregulated genes upon ectopic
expression of the KSHV miRNA cluster [42]. Further
analysis showed that suppression of MAF in KSHV-LECs
triggered the upregulation of BEC-specific genes such as
CXCR4, FTL1 and CXCL12. Although no direct inter-
action has been shown between MAF and Prox1 it has
been speculated that these transcription factors might
form a repressor complex that contributes to the suppres-
sion of the BEC markers to maintain the LEC phenotype.
Inflammatory microenvironment, lytic
reactivation and the unique, viral
transcriptional program in LECs
KSHV lytic reactivation is crucial for the virus-induced
tumorigenesis. This is demonstrated by the high viral
loads in plasma associated with the worst KS prognosis
and the clinical data indicating that inhibitors of lytic
replication (i.e. ganciclovir and forscarnet) have a preven-
tive effect on KS recurrence [43–45]. However, given that
reactivation occurs in as little as 2% of the SCs and that
upon completion of productive lytic replication phase
KSHV-infected cell dies [46], how can an event occurring
in such a small and destined to die cell population be
important for tumorigenesis? To explain these apparently
contradictory facts, a so-called paracrine effect has been
hypothesized [47]. During the lytic phase virtually all
viral ORFs are expressed. Several ORFs can manipulate
the cellular signaling thus inducing the secretion of pro-
inflammatory and angiogenic factors and modulating the
behavior of SCs in the tumor microenvironment. For
instance, ectopic expression of a lytic KSHV protein
vGPCR in ECs in vitro and in vivo increases the expres-
sion and secretion of several angiogenic and inflammatorywww.sciencedirect.com
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atic shut-off of cellular transcripts during the lytic phase
[49]. Therefore, the viral manipulation of the host
secretome upon expression of a single viral protein
may not faithfully recapitulate what happens in virus-
infected cells during lytic replication. Although some
transcripts for cytokines (e.g. IL6, IL1) can escape the
shut-off, a dramatic reduction in the induction of pro-
inflammatory and angiogenic factors was observed when
comparing lytic cells expressing vGPCR versus KSHV-
infected cells [50,51].
Lytic reactivation is also important to maintain a popula-
tion of infected cells within the tumor. ECs, in fact,
inefficiently maintain the latent infection and they lose
the episome after a few rounds of cell division both in vivo
and in vitro [52]. Lytic replication therefore would be
needed to constantly produce new virions that can infect
the uninfected cells in the affected tissue. This can be
seen as an interesting strategy evolved by the virus to
survive and successfully establish a life-long latent infec-
tion in a cell type (endothelial) that the virus is unable to
immortalize. Despite numerous attempts to propagate
cultures of KS biopsies, there are no patient-derived
endothelial cell lines stably harboring KSHV [53–56],
while several B cell lines stably and latently infected
with KSHV have been established from PEL patients
[57]. These experimental observations support the notion
that, in order to survive in certain cell types, KSHV adopts
strategies that are different from those developed for
infected B cells.
Several reports have suggested that, in some cellular
contexts a dysregulated viral transcriptional program
exists that is not ascertainable to either of the latent or
lytic viral phases [58,59,60,61]. This dysregulated gene
expression program is characterized by sporadic expres-
sion of lytic markers without efficient production of
virions and it was initially observed upon KSHV infection
of murine cells [58,59]. In particular, murine bone mar-
row-derived endothelial progenitors expressed many lytic
markers upon KSHV infection, and could generate KS-
like tumors in mice [58]. However, the relevance of these
models has been questioned since mice are not permis-
sive hosts for KSHV.
More recently, a similar viral transcriptional program has
been described also in KSHV-LECs [60]. Upon infec-
tion, differently from BECs, where only the latent genes
were detected, LECs displayed a dysregulated viral gene
expression pattern. Surprisingly, the KSHV-LECs
expressed a variety of lytic ORFs and continued the host
cell proliferation, normally not observed during produc-
tive lytic replication cycle. This ‘leakage’ of lytic tran-
scripts in LECs suggests that this could represent an
abortive lytic program not producing new virions and
not leading to cell death. Although not specificallywww.sciencedirect.com addressed in the study, it is tempting to speculate that
virus-induced host shut-off is not fully effective in the
KSHV-LECs, thus allowing the ongoing cell proliferation
and perhaps secretion of inflammatory and angiogenic
factors. Furthermore, a small amount of infectious prog-
eny was produced, suggesting that a minority of KSHV-
LECs spontaneously underwent full lytic replication
cycle. Despite the low viral titers, the pool of spontane-
ously produced progeny virions might be sufficient to
expand the population of infected cells and to compen-
sate for the loss of KSHV episomes in dividing cells.
Contribution of the DNA damage response
(DDR) to KSHV pathobiology
The association between KSHV infection and KS, PEL
and MCD undoubtedly ascribes KSHV to the oncogenic
viruses. However, KSHV infection does not induce cel-
lular immortalization, thus suggesting that virus persis-
tence is required to initiate and support tumorigenesis.
Activation and manipulation of DDR, a known hallmark
of cancers in general [62] represents also a common theme
in viral oncogenesis [63,64]. DDR is activated also in the
spindle cells in KS lesions, especially in the early (patch)
and, to a lesser extent, late (nodular) stages [65]. This
observed checkpoint activation can at least partially
explain the low proliferative index of the spindle cells
in the KS tumors.
In vitro, DDR has been shown to be induced both during
latency establishment and lytic replication phase. During
primary infection of ECs, DDR is mounted as early as
30 min post infection. Interestingly, the DDR marker
gamma H2AX is localized to the viral genome right after
its delivery to the nucleus. This KSHV-induced DDR
appeared to be essential for latent gene expression and
episome replication [66]. In addition, we and others have
reported that in different KSHV-infection models the
DDR is instigated upon lytic reactivation [67–69], thus
suggesting that the virus replication induces a genomic
stress that might represent a driving force in tumorigene-
sis or that DDR could provide a favorable host cell
environment for efficient virus replication.
Although it is known that DDR, first, can function both as
an anti-cancer barrier oras a driving force in tumorigene-
sis, second, is elicited within KS lesions and third, is
activated during KSHV lytic replication, the extent of its
contribution to KSHV tumorigenesis remains to be
elucidated.
Future perspectives
Evidence coming from epidemiological, clinical and in
vitro studies supports the lymphatic origin of SCs. Here
we suggest that KSHV reprograms EC identity to estab-
lish a viral gene expression program that allows produc-
tion of new virions for continuous reinfection of ECs (or
ECPs) to maintain a persistent infection (Figure 1). InCurrent Opinion in Virology 2017, 26:156–162
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promote its own persistence (in latency) and replication
(in the lytic phase), contributes to KS tumorigenesis.
If occurring within a KS lesion, such a model might
explain several features of the disease: first, the occur-
rence of sporadic lytic markers in KS biopsies (due to the
LEC-specific viral gene expression program and/or spon-
taneous lytic reactivation); second, the presence of an
angiogenic and inflammatory microenviroment (induced
by the sporadic expression of lytic viral genes); third, the
maintenance of a population of KSHV-infected cells
within the lesion (due to the low-rate spontaneous pro-
duction of virions); fourth, the presence of DDR activa-
tion and low proliferative index in KS lesions. A recent
reportsuggests that such a dysregulated transcriptional
program occurs at least in a subset of AIDS-KS patients
[70]. Viral profiling of KS biopsies showed that in some
tumors a tight latent program was present, whereas in a
fraction of the biopsies the viral transcriptional program
included expression of both latent and lytic ORFs.
However, several issues remain unclear. For instance,
what is the role of circulating KSHV-positive ECPs,
how to conceive the ‘leaky’ lytic program with the virus
host shut-off, and what is the role of KSHV reprogram-
ming in the context of virus persistence and what is the
contribution of DDR activation and the consequent
genomic stress to KS oncogenesis?
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